Additional information
| Vial Size | 10mg [3mL] |
|---|
ADD $500 MORE FOR FREE SHIPPING YOU HAVE UNLOCKED FREE SHIPPING
$200.00
FOXO4-DRI is an experimental senolytic peptide designed to eliminate senescent cells by disrupting the FOXO4-p53 interaction. By targeting dysfunctional cells that drive chronic inflammation and tissue aging, FOXO4-DRI represents a promising frontier in longevity and regenerative medicine research. A central process contributing to the phenotype of aging is cellular senescence. The FOXO4-p53 axis has been identified as pivotal in maintaining the viability of senescent cells, and FOXO4-DRI was developed to selectively target this axis.
Become a Member and save 20% on every order.
Become a Member| Vial Size | 10mg [3mL] |
|---|
All products sold by Stackhaus Research are intended exclusively for in vitro laboratory research purposes. These products are not approved for, and may not be used in, diagnostic, therapeutic, or clinical procedures, or for administration to humans or animals under any circumstances.
Stackhaus Research does not claim that any product has been evaluated or approved by the U.S. Food and Drug Administration (FDA) or any equivalent regulatory authority. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.
The buyer assumes full responsibility for the safe handling, storage, and lawful use of this product. Stackhaus Research, LLC is not liable for any direct or indirect damages resulting from improper handling, storage, or unauthorized use. Stackhaus Research reserves the right to refuse sales to any individual or entity suspected of misuse. By completing your purchase, you agree to these terms.